Can Pharmacy-Sold Cannabis Reduce Harm?

Legalizing cannabis is often treated as a simple choice between prohibition and commercial retail. A new Swiss study suggests that this framing overlooks what may be the most important variable: how legal access is designed.

Researchers followed 374 adults participating in Basel-Stadt’s Weed Care pilot, where recreational cannabis was distributed through pharmacies under a tightly controlled framework.¹ After one year, participants reported using cannabis slightly more frequently. However, the amount consumed per use day remained stable, while average scores for depression, anxiety, and problematic cannabis use declined.

The improvements were modest, and the study cannot prove that pharmacy access caused them. Still, the findings challenge the assumption that easier cannabis access must automatically increase harm. They also raise a more useful policy question: could a non-commercial model provide legal access without creating the same incentives found in conventional retail markets?

How Switzerland’s Pharmacy Cannabis Model Works

Weed Care is one of several authorized Swiss cannabis pilot trials designed to generate evidence for future regulation. Unlike a typical dispensary market, its purpose is not to maximize sales or attract new customers.

Participants could purchase quality-controlled cannabis from pharmacies. Products were limited to no more than 20% THC, and each participant was restricted to a maximum of 10 grams of THC per month. Prices were subsidized to remain competitive with the illicit market.

Pharmacists also provided structured counselling whenever cannabis was dispensed. This included information about lower-risk consumption, recognizing problematic use, and accessing specialist services when necessary. Participants did not receive mandatory psychotherapy or pharmacological treatment through the program.

The model therefore combined several safeguards:

• Known cannabinoid content and controlled product quality
• THC potency and monthly purchasing limits
• Repeated contact with trained pharmacists
• Harm-reduction guidance and pathways to specialist care

These features matter because legalization can take many forms. A tightly regulated pharmacy system creates different incentives and risks than a highly competitive consumer market built around brand recognition, product innovation, and sales growth.

What Happened After One Year?

The study assessed cannabis use, problematic-use symptoms, depression, anxiety, and psychotic symptoms at baseline and during follow-up. Researchers used established screening tools, including the CUDIT-R for problematic cannabis use, PHQ-9 for depression, and GAD-7 for anxiety.

The most interesting result was the apparent separation between frequency and harm. Participants used cannabis on more days per month, but they did not consume significantly more on each use day. At the same time, their average problematic-use scores fell.

This distinction supports other emerging research suggesting that frequency alone may be an incomplete measure of cannabis risk. For example, research into cannabis use and the body’s stress system found that biological differences tracked cannabis-related consequences more closely than the number of use days alone.

High-Risk Participants Experienced the Largest Change

At the beginning of the Swiss study, 126 participants met the CUDIT-R threshold for possible cannabis use disorder. Their average score declined from 16.11 to 13.89 after one year. This exceeded the two-point change that previous research has treated as clinically reliable.

However, the average follow-up score remained above the threshold for possible cannabis use disorder. Among high-risk participants with complete follow-up data, 87.4% remained in the high-risk category. The pharmacy model therefore did not eliminate problematic use, even if average symptom severity improved.

Participants who started below the high-risk threshold experienced virtually no change in their scores. This could mean that the model’s greatest potential value lies in reducing harm among people who already have more problematic consumption patterns. It could also partially reflect regression to the mean, where unusually high initial measurements naturally move closer to average during later assessments.

Risk assessment should also examine how cannabis is consumed. Recent research involving more than 17,000 American adults found that people using cannabis in multiple forms had considerably higher rates of frequent use and cannabis use disorder. A regulated system that monitors potency, product format, frequency, and consequences would provide a more complete picture than one focused on purchase volume alone.

Why Pharmacy Access Could Change Cannabis Outcomes

A pharmacy does more than replace an illicit seller. It changes the environment surrounding each purchase.

Consumers know the strength and contents of the product. They can receive guidance without entering the criminal market, and repeated interactions with pharmacists can create opportunities to identify escalating use. The model also avoids some commercial pressures that encourage producers and retailers to sell larger quantities, introduce increasingly potent products, or market consumption as part of an aspirational lifestyle.

This does not make cannabis harmless. Instead, it suggests that harm is produced by a combination of the drug, the consumer, the product, and the market surrounding it. A person buying a potency-limited product from a pharmacist operates within a different risk environment than someone purchasing an untested product illegally or selecting a high-potency concentrate from an aggressively competitive retailer.

Recent evidence from Germany offers another reminder that policy outcomes cannot be reduced to legalization status alone. Research found no immediate increase in adolescent cannabis use after partial legalization, although the researchers cautioned that longer-term monitoring remains necessary.

Taken together, these findings argue for evaluating specific regulations rather than treating every legal market as interchangeable.

The Study Does Not Prove Cannabis Improved Mental Health

The reductions in depression and anxiety scores require especially careful interpretation. Participants had relatively low average symptom levels at baseline, leaving limited room for meaningful improvement. The changes were statistically significant but small, and the proportion exceeding clinical thresholds did not decline significantly.

The study was also an uncontrolled pre-post analysis. The original Weed Care project used immediate-access and delayed-access groups during its first six months, but everyone eventually received pharmacy access. For the 12-month analysis, there was no group that remained without access for the entire period.

Researchers therefore could not separate the effects of regulated access from unrelated life changes, participation in a research project, regression to the mean, or unmeasured treatments such as psychotherapy. The findings should not be interpreted as evidence that recreational cannabis treats depression or anxiety.

Other limitations narrow the conclusions further. All cannabis and mental-health outcomes were self-reported. People with acute psychosis, severe psychiatric instability, or high suicide risk were excluded, and the average participant was almost 36 years old. This means the sample did not fully represent younger people or those most vulnerable to cannabis-related psychiatric effects.

Exposure to the regulated system was also incomplete. Approximately 51% of participants’ cannabis came from participating pharmacies, while 49% still came from the illicit market. Any observed outcome therefore reflects a mixed supply environment rather than pharmacy cannabis alone.

Legalization Is a Framework, Not a Single Policy

The Swiss findings offer a useful alternative to the usual legalization debate. The relevant question is not simply whether adults should have legal access. It is what institutions, incentives, and safeguards should govern that access.

A commercial model may reduce arrests and replace illicit sales, but it can also encourage lower prices, greater product variety, higher potency, and heavier consumption. A pharmacy model may constrain those pressures while integrating quality control, professional contact, and early intervention. Its tradeoff is that tighter controls may make it harder to fully displace illegal suppliers, as the Swiss study’s nearly even split between regulated and illicit purchases demonstrates.

The early evidence does not establish that pharmacies are the ideal cannabis retailers. It does show why governments should test multiple models and measure more than total sales or the number of people using cannabis. Relevant outcomes include potency exposure, consumption quantity, problematic use, mental health, illicit-market participation, and access to support.

Switzerland’s experiment ultimately points toward a middle position. Regulated access can exist without treating cannabis as either an ordinary consumer product or a psychiatric treatment. If longer and better-controlled studies produce similar results, pharmacy dispensing could become an important model for jurisdictions seeking to legalize cannabis while keeping public health ahead of commercial growth.

References:

¹ Pichler, E.-M., Mosandl, F., Kronschnabel, J., Meyer, M., Guessoum, A., Herrmann, O., Curiger, J., Vogel, M., Walter, M., & Baltes-Flückiger, L. (2026). Recreational cannabis access via pharmacies: A 1-year Swiss study on cannabis use and mental health. Drug and Alcohol Dependence, 113337. https://doi.org/10.1016/j.drugalcdep.2026.113337